Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England

Jamie Lopez Bernal(Public Health Agency), Mary Ramsay(University of the Witwatersrand), Claire Cameron(Health Protection Scotland), Diane Stockton(National Health Service Scotland), Elise Tessier(Public Health England), Charlotte Gower(University of Oxford), Mark G. O’Doherty(Public Health Agency), Nick Andrews(Environment Agency), Julia Stowe(Animal and Plant Health Agency), Ruth Simmons(UK Health Security Agency), Kevin Brown(UK Health Security Agency), Simon Cottrell(Public Health Wales), Jim McMenamin(Public Health Scotland), Richard J. Roberts(Public Health Wales), Chris Robertson(University of Strathclyde)

medRxiv

March 2, 2021

10.1101/2021.03.01.21252652

Cited by 204

Related Papers

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

|BMJ|2021|1.4k

The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study

|The Lancet|2021|740

Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium

|BMJ|2015|551

Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data

|The Lancet Digital Health|2021|536

The changing and dynamic epidemiology of meningococcal disease

|Vaccine|2011|304